Professor Peter Bannister, our Healthcare Sector Executive Chair, discusses how artificial intelligence (AI) can help us address the central challenges in drug discovery today. Dr Ronjon Nag, the founder of R42 Group, explores which AI techniques have the greatest potential to accelerate drug discovery. Key questions we answer include:
- How is AI being deployed for the rapid development of drugs to treat Covid-19?
- How can we harness AI to step up production of new drug candidates?
- Can AI accelerate the development of vaccines for new contagious diseases?
- How can data science be mobilised to adapt clinical trials for pandemic conditions?
The report features four case studies showcasing how AI is giving developers the edge in the race for new remedies.
These include British scale-up Healx, Oxford Drug Design, an AI-powered research portal, and Birmingham University.
To support the acceleration of AI for drug discovery and the reduction of attrition rates, ultimately making more novel drugs available to citizens in a faster and cheaper way, we made five key recommendations.